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RETINAL VEIN OCCLUSION 
INTRODUCTION 
Retinal vein occlusion is a retinal vascular disorder due to blockage of retinal 
vein either, the central retinal vein or any of the branch retinal veins, 
characterised by engorgement and dilatation of the retinal veins with secondary, 
mostly intraretinal haemorrhages and intra retinal edema, retinal ischemia 
including cotton wool spots, retinal exudates and macular edema and is usually 
associated with a variable degree of visual loss. 
Retinal vein occlusion is a common cause of vision loss. It is the second most 
common cause of reduced vision due to retinal vascular disease, after diabetic 
retinopathy. 
 
HISTORY 
The dramatic picture of retinal vein occlusion was initially described as „retinal 
apoplexy‟ by Liebreich in 1854. Leber in 1877 reported the first case of BRVO 
and called it „hemorrhagic retinitis‟. It was first established as a clinical entity 
due to thrombosis by Julius von Michel in 1878. Koyanagi in 1928 first reported 
the association between BRVO and AV crossings. 
 
 7 
 
 INCIDENCE 
The incidence of vein occlusion is 0.7% for the age group 49-60 years and 4.6% 
after the age of 80 years. It is currently estimated that there are about 520 new 
RVO cases per million people, of which 442 are BRVO and 80 are CRVO 
cases.
 1
 RVO typically occurs in middle aged and elderly individuals (older than 
50 years), with an equal gender distribution. 
 
ANATOMY 
The four branch retinal veins, superior nasal and temporal and the inferior nasal 
and temporal veins, join to form the central retinal vein. Blood supply to 
specific retinal quadrant comes exclusively from the specific retinal artery and 
vein. Arterio-venous crossings occur more often in the upper temporal quadrant 
with the vein usually lying deeper than the artery at these crossings. 
 
HISTOLOGY 
The major branches of central retinal vein have thin walls made up of single 
layer of endothelial cells having a thin basement membrane, media is composed 
of elastic fibres, few muscle cells and a thin adventitia. The retinal artery and 
vein share a common adventitial coat.
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PATHOPHYSIOLOGY 
The exact pathogenesis is not understood fully. The clinical picture of CRVO 
may be explained by occlusion of main trunk of central retinal vein. Within the 
retrolaminar portion of optic nerve, the central retinal artery and vein are 
aligned parallel to each other in a common tissue sheath. They are compressed 
as they pass through rigid sleeve like openings in the lamina cribrosa. In 
addition, compression by an atherosclerotic central retinal artery may 
predispose to CRVO. The central retinal vein may also be subject to 
compression from mechanical stretching of lamina from increased IOP. Optic 
nerve head swelling and orbital disorders may also contribute to mechanical 
compression of the vein. Hemodynamic alterations such as diminished blood 
flow, increased blood viscosity and altered lumen wall (Virchow‟s triad) may 
lead to subsequent thrombus formation. CRVO is believed to result from 
thrombotic occlusion of the central retinal vein at or just posterior to the lamina 
cribrosa.  
BRVO occurs at the AV crossing sites. At this site, the vessels have a common 
adventitial sheath. The artery lies anterior to the vein making the vein 
vulnerable to compression by the artery, resulting in turbulent flow, and 
predisposes to endothelial damage and thrombus formation. This is exacerbated 
by arteriosclerosis.
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 RISK FACTORS 
     Ocular risk factors 
 Glaucoma 
 Ischemic optic neuropathy 
 Pseudotumour cerebri 
 Tilted optic nerve heads 
 Optic nerve head drusen 
 Systemic risk factors 
 Diabetes mellitus 
 Hypertension 
 Carotid insufficiency 
 Hyperlipidemia 
 Vasculitis 
 Haematological disorders – 
 Hyperviscosity syndromes ,Lymphoma, leukemia,Anemia,elevated 
plasma homocysteine,factor XII deficiency,anti-phospholipid antibody 
syndrome, protein C protein, S deficiency, factor V Leiden mutation 
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CLASSIFICATION OF RETINAL VEIN OCCLUSION 
CRVO – whole retinal venous system is involved 
BRVO – involves only branches of retinal venous network 
HRVO – if superior or inferior hemisphere of fundus is involved 
 
CLASSIFICATION OF CRVO 
1. Perfused/ Non ischemic / Partial 
2. Non perfused/ Ischemic/ Complete/ Haemorrhagic 
3. Indeterminate 
CLASSIFICATION OF BRVO 
1. Perfused/ Non ischemic 
2. Non perfused/ Ischemic 
Based on site of obstruction 
Major BRVO 
Macular BRVO 
Peripheral BRVO
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CRVO-CLINICAL FEATURES 
SYMPTOMS 
It can present with sudden painless loss of vision, transient obscuration of vision 
and visual field defects. 
SIGNS 
1. Visual acuity can range from 20/20 to even no PL in those with neovascular 
glaucoma. Visual acuity can be helpful in distinguishing perfused versus 
nonperfused CRVO. 
2. Pupillary reaction - RAPD may be present in ischemic CRVO. It is measured 
by using neutral density filters. 
3. Intra ocular pressure is elevated in case of glaucoma. Relative intraocular 
pressure difference is less helpful in the evaluation process. Immediately after 
CRVO, the IOP is typically lower in the affected eye as compared to the fellow 
eye. This relative difference diminishes with time and symmetry returns over 
the ensuing weeks to months. 
4. Visual fields 
Visual field testing is widely variable in CRVO. Abnormalities are more 
common and more severe in eyes with nonperfused rather than perfused CRVO. 
5. Slit lamp examination may reveal iris new vessels. 
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7. Gonioscopy is essential to determine angle new vessels or angle closure from 
peripheral anterior synechiae. 
8. Ophthalmoscopic examination 
Typical features include superficial haemorrhages and deep blot haemorrhages 
in all four quadrants with dilated tortuous retinal venous system. The 
haemorrhages radiate from optic nerve head and are variable in quantity and 
may result in classic “blood and thunder” appearance. Optic nerve head 
swelling, cotton wool spots, splinter haemorrhages and macular edema are 
present to varying degree. Break through vitreous haemorrhage may be 
observed. An epiretinal membrane (ERM) may also develop. Optico-cilliary 
shunt can develop on optic nerve head, a sign of newly formed collateral 
channels with the choroidal circulation. Neovascularisation elsewhere (NVE) or 
neovascularisation at the disc (NVD) may develop as a response to secondary 
retinal ischemia. Fibrovascular proliferation from NVE/NVD may result in 
vitreous haemorrhage and tractional retinal detachment.
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SEQUELAE 
Vision 
The Central Retinal Vein Occlusion Study (CVOS) 
2
 reported that eyes with 
initial visual acuity >20/40 or better have more favourable visual prognosis. 
Patients with vision worse than 20/200 remain at this level or deteriorated 
further. 
Conversion from Ischemic to Non-Ischemic CRVO 
Ischemia observed initially may be only relative. Delayed circulation resulting 
from vascular stasis, as well as inflammation of vessel wall, are reversible with 
development of collaterals. 
Eyes with initially good vision can also become ischemic subsequently and the 
development of ischemia is more rapid in the first four months. 
Neovascularisation 
 The strongest predictor of iris neovascularisation and angle neovascularisation 
was extent of capillary nonperfusion seen by FFA. Neovascularisation is first 
detected by gonioscopy as a fine vascular network adjacent to trabecular 
meshwork. Next it can be seen in the pupillary margin, causing ectropion uveae. 
Elevated intraocular pressure associated with NVI/NVA is the hallmark of 
neovascular glaucoma. Two clock hours of NVI or any NVA is significant 
anterior segment neovascularisation. 
 14 
 
Macular Edema 
Macular edema is a major complication of both ischemic and nonischemic 
CRVO. It is caused by severe capillary leak primarily into the outer plexiform 
layer. The exact mechanism causing the leakage is unknown, but may be due to 
vascular congestion, capillary damage or localised inflammatory reactions. 
Chronic macular edema is associated with poor visual prognosis and needs to be 
treated. 
Macular Ischemia 
Inadequate blood supply to macula leads to macular ischemia which causes 
decreased vision. Presence of ischemia is confirmed ophthalmoscopically by 
cotton wool spots and attenuated arteries in and around macula. 
Fellow Eye Involvement 
The existence of systemic risk factors make the fellow eye similarly vulnerable. 
It has been reported that 5 -10% patients with CRVO develop retinal vein 
occlusion in the fellow eye.
3-6
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BRVO 
SYMPTOMS 
The symptoms are painless decreased vision, complete loss of vision or a blind 
spot in the visual field. 
SIGNS 
Features are similar to CRVO, except that the changes are localised to single 
quadrant. Segmentally distributed intraretinal haemorrhages, cotton wool spots, 
narrowing and sheathing of adjacent artery are seen. At later stages, visual 
complications may include macular edema, vitreous haemorrhage from 
neovascularisation, epiretinal membrane or retinal detachment. Clues suggestive 
of an old BRVO include segmental microvascular abnormalities and intraretinal 
collateral vessels draining across the median raphe. In nonperfused cases, 
sclerosis and sheathing of the retinal veins and arteries in the distribution of the 
occlusion may be observed. Supero-temporal branch retinal vein is most 
commonly affected. 
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COMPLICATIONS 
The complications after BRVO are macular oedema, neovascularisation, 
vitreous hemorrhage and retinal detachment. 
Macular Edema 
It is the most common complication leading to vision loss. It occurs in 5-15% of 
eyes with BRVO over a period of one year.
7 
Interleukin-6 and VEGF have been 
implicated in the development of macular edema following nonperfused BRVO.   
Neovascularisation 
Larger areas of persistent retinal nonperfusion can lead to neovascularisation of 
the retina or disc. The most common site of neovascularisation following 
BRVO is the retina. 
Optic disc neovascularisation is much less common and iris neovascularisation 
is rare in BRVO. The incidence of retinal neovascularisation is increased in 
eyes with five disc diameters or more of retinal nonperfusion. Retinal 
neovascularisation typically develops at the border between perfused and 
nonperfused retina. 
Vitreous Haemorrhage 
It may develop after rupture of thin thin, friable neovascular vessels that grow in 
response to retinal nonperfusion. 
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Retinal Detatchment 
Tractional retinal detachment can form following BRVO, if fibrovascular 
proliferation develops. Rhegmatogenous retinal detatchments are a rare 
complication of BRVO. They typically form following posterior retinal breaks 
caused by fibrovascular proliferation and traction. Nonperfused retina can lead 
to degeneration and retinal hole formation. Exudative retinal detatchment can 
occur in area of occlusion and are usually associated with nonperfusion. 
Other visually significant complications of BRVO include epiretinal membrane 
formation, retinal pigment epithelial irregularity, and subretinal scarring. 
 
Fellow Eye Involvement 
BVOS reported 9% bilateral involvement.
8, 9
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DIFFERENTIAL DIAGNOSIS 
1. Hypertensive retinopathy 
Grade 4 hypertensive retinopathy is associated with disc oedema, dilated 
veins, intraretinal haemorrhages and cotton wool spots. However, it is 
bilateral and symmetrical. AV crossing changes are prominent. Macular 
oedema is rare. 
2. Diabetic retinopathy 
Intraretinal haemorrhages and cottonwool spots are seen, but optic disc 
oedema is absent, venous pulsations are present and it is bilateral. 
3. Papilloedema 
Hemorrhages are not as extensive as in CRVO and it is also bilateral. 
4. Ocular ischemic syndrome 
It is typically associated with mid-peripheral blot-like hemorrhages, iris 
neovascularization, and ocular pain. OIS is associated with decreased 
arterial perfusion which is tested by applying light digital pressure on the 
globe and looking for central retinal artery pulsations. 
5. Hyperviscosity syndromes (e.g. polycythemia vera, sickle cell disease, 
leukemia, and multiple myeloma) 
6. Anemic retinopathy 
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 INVESTIGATIONS 
SYSTEMIC INVESTIGATIONS 
A systemic workup is not indicated in persons older than 60 years of age with 
known systemic vascular risk factors for CRVO. Younger patients are more 
likely to have predisposing conditions resulting in thrombotic disease. A limited 
systemic work up may be considered in those with a prior occlusion in fellow 
eye, prior systemic thrombotic disease, family history of thrombosis, or other 
symptoms suggestive of haematologic or rheumatologic condition. 
 Medical investigations of underlying systemic risk factors should be done.  
Blood pressure, random blood sugar, lipid profile, ECG, echocardiography, 
chest x-ray should be done. Erythrocyte sedimentation rate, anti nuclear 
antibody, anti phospholipid antibody, fasting plasma homocysteine levels must 
be done. 
FFA 
FFA is done in vein occlusions after the haemorrhages resolve. 
It helps to differentiate between ischemic and nonischemic type. In ischemic 
CRVO, the extent of capillary nonperfusion is more than 10 disc diameters. It 
also helps to evaluate capillary nonperfusion areas at the posterior pole and in 
the periphery. It can find out new vessels, collaterals, the site of obstruction, 
macular ischemia and macular edema. 
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OCT 
This investigative modality is used for diagnosis and follow-up. It is a non-
invasive technique. It can be used to quantify macular oedema and make 
comparisons over time. It can also demonstrate the presence of epiretinal 
membranes. 
ERG 
In CRVO, „b‟ wave amplitude is reduced to less than 60% of the normal mean 
value or as compared with the fellow normal eye. The „b‟ wave arises from the 
bipolar cells and Mueller cells in the inner nuclear layer which gets its blood 
supply from retinal circulation. Hence „b‟ wave is reduced in CRVO while the 
„a‟ wave arising from the photoreceptors which gets blood supply from the 
choroidal circulation is not affected. As a result, the b/a ratio is reduced in 
CRVO. 
VISUAL FIELDS 
Visual fields may be variable in CRVO while BRVO can have quadrantic field 
defects or scotomas 
NEUTRAL DENSITY FILTERS 
It is used to quantify RAPD, which may be present in ischemic CRVO.
 21 
 
MANAGEMENT 
Medical Therapy 
Identification and treatment of systemic vascular risk factors, such as systemic 
hypertension and diabetes mellitus is important. Prompt initiation of treatment 
for underlying medical conditions may avert the progression or resolve the 
existing occlusion.
10
 
Anticoagulants, fibrinolytic agents and antiplatelet drugs appear logical , but 
results  from trials  have been disappointing, with limited evidence of any 
benefit, owing to adverse effects of retinal and vitreous hemorrhage. 
Oral petoxifylline is a vasodilator and improves perfusion to occluded vessels. It 
has been tried in combination with systemic hemodilution. 
Several studies have suggested a beneficial effect of hemodilution as a therapy 
in the early phase of RVO. Hemodilution is expected to prevent the slowdown 
of blood circulation and its complications by dramatically lowering blood 
viscosity. Hemodilution is recommended in recent-onset CRVO and BRVO 
when there are no contraindications to treatment.
11
 
Systemic steroids and immunosupressives are indicated in inflammatory venous 
occlusions.
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MANAGEMENT OF CRVO 
 Classification of CRVO Subtypes 
The first step in CRVO management is represented by the differential diagnosis 
between nonischemic CRVO and ischemic CRVO, with an evaluation of 
nonperfused capillary areas at the posterior pole and of the presence/extension 
of nonperfused zones at the periphery. 
 
In nonischemic CRVO, major vision-threatening complications are macular 
edema and conversion to ischemia. 
 
In ischemic CRVO, a major vision-threatening complication is the development 
of ocular neovascularization, especially in the anterior segment of the eye (iris 
and angle, up to neovascular glaucoma). 
 
Fluorescein angiography showing extensive (more than 10 disc areas of 
nonperfusion) retinal capillary nonperfusion suggests ischemic CRVO. 
The presence of macular ischemia is seen as enlargement of the foveal avascular 
zone on fluorescein angiography.
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Management of nonischemic CRVO 
In patients with nonischemic (well-perfused) CRVO and good VA (better than 
20/40), the prognosis is favourable and monitoring is possible. In this case, no 
immediate therapy needs to be advised, but there still is a need to screen all new 
patients for vascular risk factors such as hypertension, dyslipidemia and 
diabetes. Treatment of these underlying causes is of paramount importance to 
prevent complications. An investigation of other risk factors should be 
considered only when the clinical history suggests their presence, in the absence 
of other obvious etiology. Local factors predisposing to or associated with 
CRVO, such as open-angle glaucoma, should be ruled out and treated 
appropriately to reduce the risk of progression to a more ischemic state. 
Monitoring during follow-up is aimed at identifying persistent macular edema 
and/or conversion to ischemic CRVO. Key elements in the clinical examination 
include VA assessment, biomicroscopy and OCT. Fluorescein angiography 
should be performed whenever there is doubt regarding progression, or to assess 
the degree of ischemia. 
Patients should be monitored monthly for the first 3 months, and then every 2 
months for the first year. During this monitoring period, patients should be 
instructed to return promptly whenever they notice a decrease in vision, a 
possible indication of macular edema, or the conversion to ischemic CRVO. 
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Nonischemic CRVO and VA of 20/40 or Less 
In nonischemic CRVO, with a VA which is 20/40 or less, one should search for 
macular edema. In case of macular edema, treatment should be initiated rather 
than observation. 
Management of Macular Edema in Well-Perfused CRVO 
1. Laser Photocoagulation 
In the CVOS, even though grid laser photocoagulation was able to reduce 
macular edema, there was no statistically significant VA benefit, except for the 
younger patient group. Thus, grid laser photocoagulation is not currently 
indicated.
12
 
Current treatment options include corticosteroids and antivascular endothelial 
growth factor (VEGF) approaches. Eyes affected by macular edema secondary 
to CRVO must be considered for treatment whenever VA is lower than 20/40.  
2. Corticosteroids Approach 
The rationale for the use of steroids to treat macular edema is related to their 
ability to reduce capillary permeability, and to inhibit the expression of VEGF 
gene and the metabolic pathway of VEGF. The corticosteroids used are 
Dexamethasone and Triamcinolone acetonide. 
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2.1. Dexamethasone 
Dexamethasone has been used for a long time as a potent corticosteroid that 
decreases inflammatory mediators implicated in macular edema. 
Dexamethasone is highly soluble and has a short half-life following intravitreal 
injection. To provide a sustained delivery of dexamethasone, a slow release, 
biodegradable implant (Ozurdex; Allergan) was developed, providing 
medication for up to 6 months at the posterior pole following implantation in 
the vitreous cavity. Its therapeutic effects on macular edema associated with 
RVO were investigated in a 6-month, randomized, controlled clinical trial (the 
Ozurdex GENEVA study).
13
 A prefilled, single-use applicator containing 0.7 
mg of dexamethasone in a slow-release polyglycolate-acetate implant allows the 
insertion of the drug. The Ozurdex GENEVA study demonstrated that the 
biodegradable implant containing 0.7 mg of dexamethasone (Ozurdex) resulted 
in improved VA, revealing a peak effect after 2 months and a progressive 
decline to baseline values at 6 months. The data on safety showed a low cataract 
rate and low rates of intraocular pressure increases. The study was also able to 
show that early treatment of macular edema was more beneficial than delayed 
treatment in restoring VA.  It is likely that a dexamethasone implant should be 
reinjected more frequently, following the individual response of each patient 
over the follow-up. Ozurdex has received FDA and EU approval for the 
treatment of adult patients with macular edema following CRVO. 
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2.2 Triamcinolone acetonide 
Triamcinolone acetonide has a number of side effects including the 
development of cataract and raised intraocular pressure. The presence of benzyl 
alcohol also leads to an increased risk of sterile endophthalmitis.  The 
multicenter SCORE trial
14-16 
has confirmed the beneficial effects of intravitreal 
triamcinolone acetonide for the treatment of macular edema associated with 
nonischemic CRVO. For the purpose of this study, a preservative-free 
triamcinolone preparation (Trivaris; Allergan) was used. The odds of achieving 
the primary outcome were 5.0 times greater both in the 1-mg group and in the 4-
mg group than in the observation group (p = 0.001). There was no difference 
identified between the 1-mg and 4-mg groups (p = 0.97). The 1-mg dose 
showed a better safety profile compared with the 4-mg dose, with lower 
incidence rates of raised intraocular pressure, cataract formation, progression 
and surgery 
 At present there is no evidence to suggest that the visual and anatomical 
responses seen with Trivaris in the SCORE study would be achieved with off-
label intravitreous triamcinolone acetonide preparations such as Kenalog. 
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3. Anti-VEGF Approach 
Anti-VEGF agents reduce the capillary permeability and hence are used in the 
treatment of macular oedema due to CRVO. Intravitreal anti-VEGF 
administration of ranibizumab, bevacizumab and pegaptanib have been 
investigated. 
3.1. Ranibizumab 
Ranibizumab is a pan-VEGF blocker (Lucentis ; Novartis) proved to be 
effective in the CRUISE trial.
17
  Overall, the 12-month results suggested that the 
visual gain could be sustained. Moreover, earlier treatment could lead to a 
greater functional improvement than delayed therapy. Ranibizumab 0.5 mg has 
received a license for the treatment of macular edema following RVO. 
3.2. Bevacizumab 
Bevacizumab is a pan-VEGF blocker (Avastin ; Roche) and is unlicensed for 
intraocular use. Although there is no randomized clinical trial involving 
bevacizumab in RVO, many uncontrolled case series have reported that 
intravitreal administration can lead to a VA improvement and resolution of 
macular edema. However, because of the variation in dosing and treatment 
regimens among these studies, both long-term outcomes and safety data remain 
unclear. The drug has the advantage to be less costly, which has helped its 
widespread use. 
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3.3. Pegaptanib 
Pegaptanib is a selective anti-VEGF 165 blocker (Macugen; Pfizer). The first 
multicenter randomized study on the effect of anti-VEGF therapy in the 
treatment of RVO was designed to evaluate the efficacy of pegaptanib sodium. 
A phase II trial
18
 indicated that 0.3 mg intravitreal pegaptanib given every 6 
weeks over a 6-month follow-up improved VA by approximately 7 letters at 6 
months. The best treatment regimen and response to treatment in the long run 
still remain unclear. 
Recommendations for Further Follow-Up 
Follow-up after the initial 6 months will depend upon whether steroid or anti-
VEGF treatment was initiated for macular edema, but it will normally be 
required for up to 2 years in uncomplicated cases. The eyes should be monitored 
for conversion to ischemia and for occurrence/recurrence of macular edema. 
The development of disk collaterals and the resolution of macular edema should 
lead to discharge from close clinical supervision, but the risk of conversion 
remains present and should be explained to the patients. 
Recurrence or persistence of macular edema, should lead to a decision of 
reinjection during the follow-up period. Additional laser photocoagulation could 
be suggested for nonresponding or partially responding patients, or for patients 
not complying with multiple reinjections. 
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Management of Ischemic CRVO 
In patients with ischemic CRVO, primary evaluation should assess the presence 
of macular perfusion as well as the existence of neovascularization. 
1. Macular Perfusion 
In cases with macular edema and a still perfused macula, the same treatment as 
outlined above for cases of nonischemic CRVO should be initiated. In case of a 
macula which is nonperfused, treatment should be initiated even if the 
expectation of visual improvement remains limited. 
2. Peripheral Nonperfusion 
Ischemic CRVO is usually characterized by peripheral retinal nonperfusion 
greater than 10 disc diameters, as evaluated by FFA. Development of ocular 
neovascularization is directly related to the extent of nonperfusion. Cases with 
extensive retinal nonperfusion, or with limited compliance, may be considered 
for early PRP in an attempt to block the development of ocular 
neovascularization. In less severe cases, scatter treatment directed at the 
nonperfused areas may be sufficient. In addition to treatment for macular 
edema, patients with ischemic CRVO without neovascularisation should be 
followed up at least monthly, undergoing VA, biomicroscopy, OCT and FFA (if 
needed). The corneal angle and iris should also be examined in an attempt to 
discover early neovascular tufts.
19  
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Management of Neovascularization 
1. Anterior Segment Neovascularization 
Whenever anterior segment neovascularization (angle and/or iris 
neovascularization) is identified, evidence based medicine supports the 
administration of PRP. In particular, the extent of anterior segment 
neovascularization (which explicitly requires PRP) has been defined as any 
angle neovascularization and/or 2 clock hours of iris neovascularisation. 
A complete PRP can be achieved in single or multiple sessions to cover the 
entire retina from the periphery to the vascular arcades. PRP generally requires 
a minimum of 1,500–2,000 burns, or even more, of 500 micron size, with 0.1 
second applications. Laser burns should be placed 1 burn width apart with 
sufficient energy to produce a pale white burn in the retina. Treatment is usually 
placed trying to avoid areas of retinal hemorrhage. The laser application must 
begin with the inferior quadrants, may be completed in a few weeks, and can be 
repeated whenever anterior segment neovascularization fails to regress. 
Even though there is no randomized clinical trial of the combined therapy, it is 
reasonable to administer an intravitreal anti-VEGF agent in association with 
PRP as it may lead to faster regression of anterior segment neovascularisation. 
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2. Posterior Segment Neovascularization 
Posterior segment neovascularization (retinal and/or optic disc 
neovascularization) can develop alone or in association with anterior segment 
neovascularization. It can be treated with PRP as described above. Also, 
combined treatment with anti-VEGF and PRP may prove useful to effectively 
control the growth of neovascularization. Monotherapy with intravitreal 
injection of anti-VEGF agents such as ranibizumab and bevacizumab can lead 
to a transient regression of ocular neovascularisation. 
Patients presenting with widespread ocular neovascularisation should be treated 
with PRP as soon as possible. Especially in eyes with vitreous hemorrhage, the 
combined therapy with anti-VEGF agents may prove useful to stop the growing 
of ocular neovascularization, allowing at the same time the application of 
prompt PRP in a few sessions (if the vitreous hemorrhage is not too dense, 
which would then require vitrectomy and endolaser therapy). 
3. Neovascular Glaucoma 
In the case of established neovascular glaucoma, intravitreal bevacizumab has 
been shown to cause regression of iris new vessels and decrease angle 
obstruction. Iris new vessels regress faster after intravitreal bevacizumab with 
PRP than with PRP alone. Bevacizumab may reduce the need for surgical 
interventions and serve as a useful adjunct to filtering surgery. 
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4. Juvenile CRVO 
Juvenile CRVO, occurring in people younger than 50 years, seems to be a 
different entity regarding pathogenesis and clinical course, and should be 
differentiated from CRVO developing after 50 years of age. In some cases, 
when the disease is associated with severe systemic disease, patients need to be 
addressed for complete systemic evaluation, and the prognosis can be guarded. 
Juvenile CRVO is often of a non ischemic type, with no clearly identifiable risk 
factors, and sometimes related to an inflammatory pathogenesis, as shown by 
the detection of vitreous cells. Visual prognosis is generally better in 
comparison with ordinary CRVO, even though possible complications include 
ocular neovascularization and the development of macular edema. 
Some evidence exists that systemic steroids can lead to a faster resolution of the 
disease. Even though there is no randomized clinical trial, it is plausible that 
intraocular steroids, especially the intravitreal slow-release dexamethasone 
implant, may prove useful in the management of macular edema secondary to 
juvenile CRVO.
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MANAGEMENT OF BRVO 
The management of BRVO has many similarities to the management of CRVO 
with regard to systemic risk factors, but it presents some important differences 
because this type of RVO carries a lower risk of progressive worsening and 
conversion to ischemia and a lower risk of neovascularization. 
Thus, the management of BRVO should embrace several targets including: the 
identification and management of systemic risk factors; a precise classification 
of the area of inclusion to determine major branch versus tributary branch 
occlusion; an assessment of the degree of peripheral perfusion and degree of 
macular ischemia, and the institution of treatment according to sight-threatening 
complications (mainly persistent macular edema and neovascularization). 
BRVO with Perfused Periphery and Normal VA 
In case of a BRVO with a perfused periphery and normal VA, the prognosis is 
favorable and monitoring is possible. In this case, no therapy needs to be 
advised. In the follow-up examination, one should look for significant macular 
edema by VA examination, biomicroscopy and OCT. If in doubt, fluorescein 
angiography should be performed. Patients should be monitored monthly for the 
first 3 months, and then every 2 months for the first year. During this 
monitoring period, patients should be instructed to quickly report whenever they 
notice a loss of VA, which may indicate the development of macular edema. 
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BRVO with Perfused Periphery and Symptomatic VA Decline 
In cases of BRVO and symptomatic decline in VA, an assessment should be 
performed for the existence of macular edema. If there is macular edema seen 
by OCT, treatment should be considered according to the following outline. 
Special attention should be paid to macular BRVO, a subtype of BRVO 
involving a small vein draining a sector of the macular region, which has a more 
favorable natural course, not requiring treatment in most cases. 
1.Laser photocoagulation 
For many years, grid laser photocoagulation has been the standard care and 
recommended for patients with macular edema associated with branch vein 
occlusion who met the BVOS eligibility criteria (VA of 20/40 or less, persistent 
macular edema lasting for 4 months or longer, and resorption of macular 
hemorrhages).
8, 9
 Recently, based on the results of a new prospective, double-
masked randomized trial, the SCORE study
20
, it was recommended that grid 
photocoagulation should remain the treatment of choice for eyes with vision 
loss associated with macular edema secondary to BRVO. The study concluded 
that no difference was found in VA at 12 months in the standard care group 
(grid laser photocoagulation) compared with the triamcinolone groups. 
Moreover, rates of adverse events (particularly elevated intraocular pressure and 
cataract) were highest in the 4-mg triamcinolone group. 
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2. Intravitreal Drugs 
2.1. Intravitreal Steroids 
2.1.1. Dexamethasone 
The Ozurdex GENEVA study showed that the maximum effect was at day 60 
and a decrease in effect began at day 90, but was still persistent at day 180. The 
second injection was even slightly more effective than the first injection. No 
adverse events were related to the injection, with a very low cataract rate and 
very low rates of persistent intraocular pressure increase. 
2.1.2. Intravitreal triamcinolone acetonide 
Recently, the SCORE trial
20
 compared the efficacy and safety of 1-mg and 4-mg 
doses of preservative-free intravitreal triamcinolone with standard care (grid 
photocoagulation) for eyes with vision loss associated with macular edema 
secondary to BRVO, and concluded that there was no difference identified in 
VA at 12 months for the standard care group compared with the triamcinolone 
groups; however, rates of adverse events (particularly elevated intraocular 
pressure and cataract) were highest in the 4-mg group. 
2.2. Intravitreal Anti-VEGF Drugs 
Intravitreal anti-VEGF administration has been tried with ranibizumab, 
bevacizumab and pegaptanib. Ranibizumab was proved to be effective for 
macular oedema secondary to BRVO in the BRAVO trial. 
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Management of BRVO with Peripheral Nonperfusion 
In these cases, the perfusion of the macula should be assessed. If it is perfused, 
treatment should be contemplated as outlined above. Laser treatment of the 
peripheral areas of nonperfusion can be considered if the nonperfused area is 
very extensive. 
If the macula is not perfused, again, treatment should be contemplated as 
outlined above, with informed consent of patients as the prognosis can be bleak. 
In cases of BRVO with peripheral neovascularization, intravitreal therapy 
should be initiated, followed by scatter laser aimed at the area of the occluded 
vein. 
PREVENTION 
Only few studies have addressed the prevention of recurrence of RVO in the 
same eye, or of the development of RVO in the contralateral eye. So far, none 
of these studies have shown any benefit. Available data support the concept that 
recurrence of RVO may be reduced by medical treatment of underlying 
cardiovascular risk factors. 
Historically, hormone replacement therapy was contraindicated and 
discontinued following central vein occlusion. Currently, the decision about 
whether to continue hormone replacement therapy in women with RVO should 
be made on a case-by-case basis. 
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SURGICAL APPROACHES TO TREATING RVO 
The focus of surgical treatment is either the occluded retinal vein itself or the 
macular edema. Many surgical treatment modalities have been reported for 
RVO. Of the following common surgical approaches, only a few are frequently 
utilized: 
(1) Radial optic neurotomy (RON); 
(2) Chorioretinal venous anastomosis; 
(3) Vitrectomy with or without internal limiting membrane (ILM) peeling; 
(4) Injection of tissue plasminogen activator (t-PA) into the lumen of a retinal 
vein via retinal vein cannulation; 
(5) arteriovenous sheathotomy 
1. Radial Neurotomy  
Combined pars plana vitrectomy with transvitreal incision of nasal sclera ring, 
radial to the optic nerve and parallel to nerve fibre layer, releases the pressure 
on central retinal vein and the scleral outlet. This procedure addresses the 
compartmental syndrome. Radial optic neurotomy also induces development of 
optociliary venous anastomosis or retinochoroidal shunts, leading to increased 
retinal venous outflow. 
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 Reported complications of radial optic neurotomy include optic nerve damage, 
temporal visual feild defect, injury to central retinal artery or vein, subretinal 
hemorrhage, vitreous hemorrhage, globe perforation, peripapillary retinal 
detachment, choroidal neovascularisation and anterior segment 
neovascularization.
21-23
 The benefits of RON appear to be controversial and its 
efficacy remains to be proven in prospective randomized clinical studies.  
 
2. Chorioretinal Venous Anastomosis 
In this method, the occluded central retinal vein is bypassed by creating a 
chorioretinal anastamosis between nasal branch of central retinal vein with the 
choroidal circulation. It prevents the development of retinal ischemia. Visual 
acuity may improve as a result of resolution of macular oedema and 
maintenance of retinal perfusion. This is done surgically or by using laser.
24
 
Laser energy delivered through Nd:YAG or argon laser is directed at branch 
retinal vein to rupture the posterior vein wall and Bruch‟s membrane.  
Complications include intraretinal, subretinal and vitreous hemorrhage, 
secondary neovascularisation, fibrovascular proliferation and tractional 
detachment  
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3. Vitrectomy with or without ILM Peeling 
Pars plana vitectomy can be done in cases of nonclearing vitreous hemorrhage. 
It can be combined with epiretinal membrane peeling with endolaser 
photocoagulation if needed. Relieving the vitreous traction over the macula by 
means of vitrectomy induced PVD improves macular oedema. 
A statistically significant improvement in patients after vitrectomy with gas/air 
tamponade for macular edema caused by BRVO was reported .
25-26
 
 
4. Arteriovenous Sheathotomy 
It is an attempt to decompress the involved venule by separating the overlying 
retinal artery from the underlying branch vein by sectioning the shared 
adventitial sheath. Patients who have macular oedema recalcitrant to grid may 
be candidates for AV sheathotomy. More recently, a bimanual technique of 
arteriovenous sheathotomy followed by intravitreal recombinant t-PA is done.
27
 
Complications include nerve fibre layer defects, vitreous hemorrhage, retinal 
tear and retinal detachment. 
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AIM 
 To study the commonest etiology for retinal vein occlusion in patients 
attending Ophthalmology outpatient department. 
 To study the response to treatment in terms of visual acuity, macular 
thickness and intraocular tension. 
 To study the FFA and OCT features of retinal vein occlusions. 
 To study the prevalence of retinal vein occlusion in relation to etiology, 
age, gender, laterality, quadrant of involvement and risk factors 
 To assess the risk factors associated with retinal vein occlusion and the 
factors associated with better visual outcome 
 
METHODOLOGY 
All new and review cases attending Ophthalmology outpatient department 
diagnosed to have retinal vein occlusion were included in the study. A total of 
51 eyes of 51 patients were included in this study. 
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PROCEDURE 
A detailed history, vision, intraocular tension, slit lamp examination and fundus 
examination were done. Fundus fluorescein angiography (FFA) and Optical 
coherence tomography (OCT) were done in appropriate cases. Random blood 
sugar, BP, lipid profile and cardiac evaluation were done. The treatment was 
tailored according to individual patient. The underlying systemic disease was 
treated. For macular edema, either macular grid laser or intravitreal anti-VEGF 
injection was given. If there were new vessels or significant capillary 
nonperfusion areas seen on FFA, laser photocoagulation was done. 
 
INCLUSION CRITERIA 
All patients diagnosed to have retinal venous occlusion were included in the 
study. 
 
EXCLUSION CRITERIA 
Patients diagnosed to have vein occlusion due to vasculitis were excluded from 
the study. 
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TREATMENT 
Treatment was tailored according to individual patient. 
The underlying systemic disease was treated. If visual acuity was more than 
6/12, with no macular pathology and no significant capillary non perfusion 
areas, careful observation was done. If vision was less than 6/12, search for 
macular edema or ischemia was done. For macular edema, either macular grid 
laser or intravitreal anti-VEGF injection was given. If there were new vessels or 
significant capillary nonperfusion areas seen on FFA (more than 5 disc diameter 
areas for BRVO and more than 10 disc diameter areas for CRVO), laser 
photocoagulation was done with or without intravitreal anti-VEGF. The anti-
VEGF injection was repeated if required. 
 
FOLLOW UP 
 Follow up was done at 4, 12 and 24 weeks.
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RESULTS 
We studied retinal vein occlusions in 51 eyes of 51 patients who presented to 
Ophthalmology outpatient department. Of these, 17 had CRVO, 1 had HCRVO 
and 33 had BRVO. 
TABLE 1 PERCENTAGE OF VARIOUS TYPES OF RVO 
Types of Vein Occlusions Number (%) 
CRVO 17 (33%) 
HCRVO 1 (2%) 
BRVO 33 (65%) 
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CRVO 
 
 
HCRVO 
 
 45 
 
 ST BRVO 
  
 
MACULAR BRVO 
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TYPES OF BRVO 
Of the 33 patients with BRVO studied, 20 had ST BRVO, 10 had IT BRVO, 1 
had SN BRVO and 2 had macular BRVO. 
TABLE 2 TYPES OF BRVO 
Type of BRVO Number (%) 
ST BRVO 20 (60.6%) 
IT BRVO 10 (30.3%) 
SN BRVO 1 (3.03%) 
IN BRVO 0 (0%) 
Mac BRVO 2 (6.06%) 
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AGE DISTRIBUTION 
TABLE 3 AGE DISTRIBUTION 
Age in years CRVO (17) HCRVO (1) BRVO (33) Total (51) 
31-40 2 0 6 8 (15.6%) 
41-50 0 0 6 6 (11.7%) 
51-60 11 0 7 18 (35.2%) 
61-70 4 1 9 14 (27.4%) 
71-80 0 0 5 5 (9.8%) 
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The mean age of the patients included in the study was 56.27 ± 11.28 years, 
ranging from 35 to 76 years. Most of the patients, 32( 64.7%) were in the age 
group of 51-70 years. Patients of age less than 50 years were just 14 (27.5%), 
while patients more than 50 years were 37 (72.5%). Retinal vein occlusion is 
therefore more common in the elderly. 
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A subgroup analysis revealed that most of the patients with CRVO were in the 
6
th
 (11, 64.7%) and 7
th
 (4, 23.7%) decades, while  patients were more evenly 
distributed in the BRVO group. 
 
GENDER DISTRIBUTION 
In our study, we found male preponderance for both CRVO and BRVO, of 
64.7% and 66.7% respectively. The male preponderance could be explained by 
the increased incidence of smoking among males. 
 
TABLE 4 GENDER DISTRIBUTION 
Gender CRVO  HCRVO BRVO TOTAL 
Male 11 1 22 34 
Female 6 0 11 13 
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LATERALITY 
All the eyes studied had unilateral involvement. Twenty eight (54.9%) were 
right eyes and twenty three ( 45.1%) were left eyes.  
We found that 12 (70.6%)  of CRVO involved the right eye. In case of BRVO,  
there was no difference in involvement of either eye. 
 
TABLE 5 LATERALITY 
Laterality OD OS 
CRVO 12 5 
HCRVO 0 1 
BRVO 16 17 
Total 28 23 
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TIME OF PRESENTATION 
Of the CRVO patients, 5 (29.4%) presented within 4 weeks of the onset of 
venous occlusion, while 6 (18.1%) BRVO patients presented within 4 weeks. 
The rest of the patients presented after more than 1 month of the symptoms. 
This may be because of the fact that ours is a tertiary care ophthalmic centre, 
referred cases from peripheral hospitals came to our hospital a prolonged period 
after the onset of disease. More BRVO cases presented later than a month which 
may be because BRVO did not significantly affect vision when compared to 
CRVO. 
TABLE 6 DURATION OF DIMINISHED VISION 
Type <4 WEEKS 5-12 WEEKS 13-24 WEEK >24 WEEKS 
CRVO 5 (29.4%) 6 (35.2%) 4 (23.5%) 2 (11.7%) 
HCRVO 1 0 0 0 
BRVO 6 (18.1%) 8 (24.2%) 16 (48.4%) 3 (9%) 
Total 12 (23.5%) 14 (27.4%) 20 (39.2%) 5 (9.8%) 
 
 54 
 
 
 
Three of our CRVO patients presented after 20 weeks and had neovascular 
glaucoma. One of them had high IOP of 48 mm Hg which was managed 
medically. Susequently he underwent anti-VEGF injection and panretinal 
photocoagulation. Another patient also received anti-VEGF injection and 
panretinal photocoagulation, while the third person underwent panretinal 
photocoagulation alone. 
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FRESH IT BRVO 
 
OLD IT BRVO 
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RISK FACTORS FOR VEIN OCCLUSION 
The commonest comorbid condition was hypertension, which was found in 28 
(53%) patients. Diabetes mellitus was present in 10 (19.6%) patients. Twenty 
three (45%) patients had serum cholesterol more than 200 mg%. Four patients 
(7.8%) had a coronary artery disease (CAD) while 2 patients (3.9%) had a 
history of cerebro-vascular accident (CVA), Four patients (7.8%) had primary 
open angle glaucoma. 
 
 TABLE 7 RISK FACTORS 
Risk Factor CRVO HCRVO BRVO Total 
DM 3 (17.6%) 0 7 (21.2%) 10 (19.6%) 
HT 9 (52.9%) 1 18 (54.5%) 28 (54.9%) 
Hypercholestolemia  8(47%) 1 14 (42.4%) 23 (45%) 
CAD 0 0 4 (12.1%) 4 (7.8%) 
CVA 1 (5.8%) 0 1 (3%) 2 (3.9%) 
POAG 2 (11.7%) 0 2 (6%) 4 (7.8%) 
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Among CRVO cases, 3 (17.6%) had diabetes mellitus, 9 (52.9%) were 
hypertensive, 8 (47%) had hypercholesterolemia, 1 (5.8%) had a history of 
CVA and 2 (11.7%) had POAG. Among the BRVO patients, 7 (21.2%) were 
diabetic, 18 (54.9%) were hypertensive. 14 (42.4%) had hypercholestolemia, 4 
(12.1%) had CAD, 1(3%) had CVA and 2 (6%) had POAG 
 
 
 
The mean random blood sugar was 133 ± 36 mg%.  The mean systolic blood 
pressure was 144 ± 21 mmHg and the mean diastolic blood pressure was 90 ± 
10 mmHg. The mean serum cholesterol was 195 ± 33 mg%. 
. 
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PRESENTING VISUAL ACUITY 
Among CRVO patients, 15 (88.2%) had vision less than 3/60 at presentation, 
while only 7 (21.2%) BRVO patients had such poor vision. Also, 18 (54.5%) 
BRVO patients had presenting vision of 6/36 or better which was present in 
only 1 (5.8%) patient with CRVO. 
 
TABLE 8 PRESENTING VISUAL ACUITY 
VA CRVO HCRVO BRVO TOTAL 
6/6-6/12 0 0 3 (9%) 3 (5.8%) 
6/18-6/36 1 (5.8%) 0 15 (45.4%) 16 (31.3%) 
6/60-4/60 1 (5.8%) 0 8 (24.2%) 9 (17.6%) 
3/60-1/60 10 (58.8%) 1 7 (21.2%) 18 (35.2%) 
HM/PL 5 (29.4%) 0 0 5 (9.8%) 
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INTRAOCULAR PRESSURE 
The mean intraocular pressure at presentation was 16.8 ± 5.4 mm Hg. Ten 
patients (19.6%) had intraocular pressure more than 20 mm Hg and were 
managed medically. Four patients had primary open angle glaucoma and 3 
patients had neovascular glaucoma secondary to the vascular occlusion. CRVO 
patients had higher IOP (18.9 mm Hg) than BRVO patients (15.6 mm Hg). 
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FFA FINDINGS 
Fundus fluorescein angiography was  done in 50 patients. One patient with 
vitreous hemorrhage did not undergo FFA.  
Eight (50%) CRVO patients had capillary non perfusion areas more than 10 disc 
diameter area, 6 (37.5%) had new vessels, and 2 (12.5%) had macular oedema. 
Macular ischemia was noted in 4 (25%) of patients with CRVO. 
Of the BRVO patients, 8 (24.2%) had capillary non perfusion more than 5 disc 
diameter area, 2 (6%) had collaterals, 8 (24.2%) had new vessels, 10 (30.3%) 
had macular oedema and 2 (6%) had macular iscemia. 
The patient with HCRVO had macular ischemia and collateral formation. 
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TABLE 9 FFA FINDINGS 
FFA Finding CRVO (16) HCRVO (1) BRVO (33) TOTAL 
(50) 
SIGNIFICANT 
CNP 
8 (50%) 0 8 (24.2%) 16 (32%) 
COLLATERALS 0 1 2 (6%) 3 (6%) 
NEW VESSELS 6 (37.5%) 0 8 (24.2%) 14 (28%) 
MACULAR 
EDEMA 
2 (12.5%) 0 10 (30.3%) 12 (24%) 
MACULAR 
ISCHEMIA 
4 (23.5%) 1 2 (6%) 7 (13.7%) 
 
CRVO patients had more significant CNP areas, had increased incidence of 
neovascularisation and the presence of macular ischemia was more likely. This 
is because of the larger area of retina involved in CRVO 
 62 
 
 
 
 
 63 
 
FFA DEMONSTRATING NON FILLING OF OCCLUDED 
INFEROTEMPORAL VEIN WITH CAPILLARY NONPERFUSION 
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FFA SHOWING DEVELOPMENT OF COLLATERALS 
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FFA SHOWING SIGNIFICANT CAPILLARY NONPERFUSION WITH 
MACULAR OEDEMA 
 
FFA DEMONSTRATING MACULAR ISCHEMIA 
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FFA SHOWING LEAKAGE FROM FLORID NEOVASCULARISATION 
 
NEOVASCULARISATION ELSEWHERE 
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MANAGEMENT 
Among the CRVO patients, 8 (47%) had either extensive capillary non 
perfusion  area more than 10 disc  diameter area or evidence of new vessels and 
were hence treated with panretinal scatter laser photocoagulation. In addition to 
laser, 2 patients were given anti-VEGF injection prior to the laser. Two patients 
who had macular edema were given anti-VEGF alone (1 to 2 injection). One 
patient of CRVO who developed non-resolving vitreous hemorrhage secondary 
to neovascularisation of the disc underwent pars plana vitrectomy with 
endolaser. Another patient had spontaneous clearing of the vitreous hemorrhage 
and later underwent panretinal scatter laser photocoagulation. Patients who had 
no evidence of new vessels or capillary non perfusion area less than 10 disc 
diameter area (7 patients) were observed carefully. 
Eight (24.2%) of BRVO patients had either new vessels or capillary non 
perfusion areas more than 5 disc areas and were treated with sectoral laser 
photocoagulation. Three patients were given anti-VEGF also, in addition to 
laser. Nine (27.2%) patients were given anti-VEGF for macular oedema (1 to 3 
injections). Macular grid laser was done in 3 patients with macular oedema due  
to BRVO. Observation was done in 13 (39.3%) patients who had no evidence of 
new vessels or capillary non perfusion area less than 5 disc diameter area. One 
of them with SN BRVO had a tractional detachment of the peripheral retina and 
hence was observed. HCRVO patient had macular ischemia and was observed. 
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TABLE 10 MANAGEMENT 
MANAGEMENT CRVO HCRVO BRVO TOTAL 
OBSERVATION 7 (41.1%) 1 13 (39.3%) 21 (41.1%) 
SCATTER 
LASER 
8 (47%) 0 8 (24.24%) 16 (31.3%) 
GRID 0 0 3 (9%) 3 (5.8%) 
ANTI-VEGF 4 (23.5%) 0 11 (33.3%) 15 (29.4%) 
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SECTORAL SCATTER PHOTOCOAGULATION 
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VISUAL OUTCOME 
 At the end of 6 months of follow-up, 15 (88.55%) patients with CRVO had 
final visual acuity less than 3/60 whereas only 7 (21.2%) BRVO patients had 
vision less than 3/60. Only 1 (5.8%) CRVO patient had vision more than 6/36 
while 20 (60.6%) BRVO patients had vision more than 6/36 at the end of 6 
months. The visual outcomes were much better in BRVO when compared to 
CRVO due to the larger area of retina involved and the higher incidence of 
complications in CRVO. 
 
TABLE 11 FINAL VISUAL ACUITY 
FINAL VA CRVO HCRVO BRVO Total 
6/6-6/12 0 0 7 7 (13.7%) 
6/18-6/36 1 0 13 14 (27.4%) 
6/60-4/60 1 0 6 7 (13.7%) 
3/60-1/60 7 1 7 15 (29.4%) 
HM/PL 8 0 0 8 (15.6%) 
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CHANGE IN VISUAL ACUITY 
TABLE 12 CHANGE IN VISUAL ACUITY 
VISUAL ACUITY NUMBER AT 
PRESENTATION 
NUMBER AT 6 
MONTHS 
6/6 - 6/12 3 7 
6/18 – 6/36 16 14 
6/60 – 4/60 9 7 
3/60 – 1/60 18 15 
HM/ PL 5 8 
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At the end of 6 months of follow-up,  6 of the CRVO patients had worsening of 
visual acuity by 1 line, 8 had no change and 3 patients showed atleast 1 line 
improvement. 
In BRVO, 11 patients had worsening of visual acuity, 10 had no change and 12 
patients showed 1 line improvement. 
The patient with HCRVO had reduction of visual acuity by one line. 
However if 2 line change in visual acuity was considered, 1 patient of CRVO 
had improvement by 2 lines, while the rest 16 had no change in visual acuity by 
more than 1 line and 5 patients of BRVO had improvement in visual acuity by 2 
or more lines and the rest 28 had no change in visual acuity by more than 1 line. 
The HCRVO patient also did not have change in visual acuity by more than 1 
line.  No patient of any type had worsening of visual acuity by more than 1 line. 
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TABLE 12 CHANGE IN VISUAL ACUITY (1 line) 
VISUAL 
ACUITY 
CHANGE 
CRVO HCRVO BRVO TOTAL 
IMPROVED 3 (17.6%) 0 12 (36.3%) 15 (29.4%) 
SAME 8 (47%) 0 10 (30.3%) 18 (35.2%) 
WORSENED 6 (35.2%) 1 11 (33.3%) 18 (35.2%) 
 
TABLE 13 CHANGE IN VISUAL ACUITY (2 line) 
VISUAL 
ACUITY 
CHANGE 
CRVO HCRVO BRVO TOTAL 
IMPROVED 1 (5.9%) 0 5 (15.2%) 6 (11.8%) 
SAME 16 (94.1%) 1 28 (84.8%) 45 (88.2%) 
WORSENED 0 (0%) 0 0 (0%) 0 (0%) 
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None of the patient with macular oedema who were treated with anti-VEGF 
injection or macular grid lost more than 1 line, while 2 patients gained 2 lines 
and one patient had a dramatic 4 line improvement in vision. 
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Taking the eyes which received Avastin for macular oedema alone, 67% had 
either same or improvement in vision by atleast 1 line and 33% had decrease in 
vision by 1 line alone. None of the patients had drop in vision of more than 1 
line and 27% had improvement in vision by atleast 2 lines. 
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CHANGE IN INTRAOCULAR PRESSURE 
The mean intraocular pressure did not change much from 16.8 ± 5.4 mm Hg 
(ranging from 10 to 48 mm Hg) at presentation to 16.3 ± 2.9 mm Hg (ranging 
from 12 to 28 mm Hg). The patients with primary open angle glaucoma and 
neovascular glaucoma were under medical management. Also none of the 
patients were treated with steroids.  
 
 
 
The mean IOP in Avastin group was 17.6mm Hg before treatment and 16 mm 
Hg after treatment. 
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CHANGE IN CENTRAL MACULAR THICKNESS 
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In the 9 patients with macular oedema, who were treated with intravitreal anti-
VEGF (Avastin) injection, the mean central macular thickness changed from 
447µ to 327µ.  Prior to treatment, 66.6% had central macular thickness of more 
than 400µ. After treatment, 88.8% of the patients had central macular thickness 
of less than 400µ . 
The mean central macula thickness also reduced form 318µ to 251µ in the 3 
patients who underwent macular grid laser for macular oedema. 
OCT SHOWING GROSS MACULAR OEDEMA IN CRVO 
 
 
OCT SHOWING SEGMENTAL MACULAR OEDEMA IN BRVO 
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SUMMARY 
1. Fifty one eyes of 51 patients with retinal vein occlusion were studied. 
2. Out of the 51 cases, 17 were CRVO, 33 were BRVO and one patient had 
HRVO. CRVO constituted 33%, BRVO constituted 65% and HRVO was 
2%. 
3. Most of the patients were in their 6th  and 7th decades with a mean age of 
56.2 years. 
4. Male preponderance was noted. Overall 67% were male. This could be 
due to increased incidence of smoking in males. 
5. Of the 33 patients with BRVO studied, 20 had ST BRVO, 10 had IT 
BRVO, 1 had SN BRVO and 2 had macular BRVO. 
6. The commonest comorbid condition was hypertension, which was found 
in 28 (53%) patients. Diabetes mellitus was present in 10 (19.6%) 
patients. Four patients had cardiac abnormalities, 2 had cerebrovascular 
accident and 4 had POAG. 
7.  Among CRVO cases, 3 (17.6%) had diabetes mellitus, 9 (52.9%) were 
hypertensive, 8 (47%) had hypercholesterolemia, 1 (5.8%) had a history 
of CVA and 2 (11.7%) had POAG. 
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8. Among the BRVO patients, 7 (21.2%) were diabetic, 18 (54.9%) were 
hypertensive. 14 (42.4%) had hypercholestolemia, 4 (12.1%) had CAD, 
1(3%) had CVA and 2 (6%) had POAG. 
9. Of the CRVO patients, 5 (29.4%) presented within 4 weeks of the onset 
of venous occlusion, while 6 (18.1%) BRVO patients presented within 4 
weeks. The 3 CRVO patients who developed neovascular glaucoma all 
presented after 20 weeks. 
10. Eight (50%) CRVO patients had CNP areas more than 10 disc diameter 
area, 6 (37.5%) had new vessels, and 2 (12.5%) had macular oedema. 
Macular ischemia was noted in 4 (25%) of patients with CRVO. 
11. Of the BRVO patients, 8 (24.2%) had CNP more than 5 disc diameter 
area, 8 (24.2%) had new vessels, 10 (30.3%) had macular oedema and 2 
(6%) had macular iscemia. 
12.  If 2 line change in visual acuity was considered, 1 patient of CRVO had 
improvement by 2 lines, while the rest 16 had no change in visual acuity 
by more than 1 line . 5 patients of BRVO had improvement in visual 
acuity by 2 or more lines and the rest 28 had no change in visual acuity 
by more than 1 line. The HCRVO patient also did not have change in 
visual acuity by more than 1 line.  No patient of any type had worsening 
of visual acuity by more than 1 line.  
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13. Among the eyes which received Avastin for macular oedema, 67% had 
either same or improvement in vision by atleast 1 line and 33% had 
decrease in vision by 1 line alone. None of the patients had drop in vision 
of more than 1 line and 27% had improvement in vision by atleast 2 lines. 
14. In patients with macular oedema, treatment with Anti-VEGF injection or 
macular grid laser reduced the central macular thickness. 
15. There was no significant change in the mean intraocular pressure on 
followup.
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CONCLUSIONS 
 Retinal venous occlusions are common in the 6th and 7th decades 
 It is seen more commonly in males. 
 The most common predisposing factor for retinal vein occlusion was 
hyertension. 
 Branch retinal vein occlusions were commoner than central retinal vein 
occlusions and had better visual outcomes. 
 All the patients had either same visual acuity or had improvement in 
visual acuity by 2 or more  lines.  None of  them  had worsening of visual 
acuity by more than 1 line. 
 In our study, 9 patients with macular edema were treated with anti-VEGF                 
and 3 were treated with grid laser. In both these groups, the mean central 
macular thickness was reduced after treatment. 
 Finally we conclude that 
o In CRVO, final vision is limited despite available treatment. 
However, regular monitoring is required to detect and treat 
complications. 
o In BRVO, there is chance for visual improvement in patient with 
initial good vision. 
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PROFORMA 
A CLINICAL STUDY ON RETINAL VASCULAR OCCLUSIVE DISORDERS 
Name     Age  Gender  OP/IP No 
Address        Date 
 
Presenting Complaints 
Defective Vision  Yes/No  OD/OS  Duration  Sudden/Gradual 
Field Loss  Yes/No  Quadrant 
Floaters/Flashes/Macropsia/Micropsia/Metamorphopsia/Scotoma 
Any other symptoms 
Past History 
Similar illness          
Glaucoma         Drug history 
HT/DM/Hyperlipidemia/CVS diseases/Blood dyscrasias/Infections   Duration 
Personal History 
Smoking/Alcohol 
Family History 
Ocular Examination 
BCVA      OD    OS 
IOP 
RAPD  
Anterior segment examination 
(NVI/NVA) 
Fundus examination 
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Investigations 
FFA 
Site of occlusion/CNP/Collaterals/New vessels 
Macular oedema/ischemia 
Disc leakage/Staining of vessel walls 
OCT 
 
 
 
 
 
Visual Fields 
BP 
RBS    Hb  TC  DC  ESR  
Peripheral smear   Platelets   BT  CT 
Blood urea   Creatinine 
Lipid profile 
Urine albumin/sugar 
VDRL    Mantoux   CXR 
Cardiology opinion 
Septic foci-ENT/Dental/Skin/VD/Gynaec 
 
Treatment given 
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Follow up 
 4 weeks 12 weeks 24 weeks 
BCVA    
IOP    
Anterior segment 
 
 
   
Fundus 
 
 
 
 
 
   
OCT 
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OP No Name Age Sex Eye Diagnosis DV duration(weeks) Risk Factors RBS BP S cholesterol Initial VA Initial IOP FFA findings Initial CMT Treatment No of Avastins Final VA Final IOP Final CMT Complications
1 69989 CHANDRA 50 F OS ST BRVO 1 HT 80 200/100 227 6/12 16 CNP Observation 6/12 14
2 468934 JANAKIRAMAN 61 M OS IT BRVO 24 POAG 96 120/86 210 3/60 14 CNP Observation 3/60 16 ERM
3 78929 ELUMALAI 44 M OS IT BRVO 8 Nil 102 112/78 192 6/18 14 CNP Observation 6/24 12
4 857 RAJAN 54 M OD CRVO 1 CVA/DM 120 140/80 230 1/60 18 ISCHEMIA Observation 1/60 18
5 4732 DAMODARAM 76 M OS ST BRVO 4 HT/CAD 94 170/110 168 3/60 10 CME 468 Avastin 3 6/36 16 276 ME
6 396 PREMKUMAR 53 M OD CRVO 1 HT 90 150/100 200 1/60 14 ISCHEMIA Observation HM 12
7 4826 PONNI 50 F OS ST BRVO 1 HT 120 160/100 250 6/60 18 CME 397 Avastin 2 6/24 14 337 ME
8 12047 VENKIAH 58 M OD CRVO 22 HT 130 170/100 170 1/60 48 NVD/NVE/CNP PRP/avastin HM 28 NVG
9 759 VISWANATHAN 51 M OD CRVO 1 POAG 100 110/80 205 1/60 22 CNP Observation/AGM 1/60 18
10 6548 KANNIAPPAN 51 M OS Mac BRVO 8 HT 94 160/90 161 6/18 16 CME 321 Avastin 1 6/12 12 267 ME
11 15694 MARIAMMAL 65 F OS IT BRVO 12 HT 125 170/90 211 6/60 20 CNP Observation 6/60 18
12 14824 GANDINESAN 47 M OS IT BRVO 4 Nil 134 150/90 242 6/18 18 CNP Observation 6/12 18
13 4146 DASARATH 60 F OS CRVO 4 HT 79 150/100 152 HM 18 ME 544 Avastin 2 HM 16 323 ME
14 7215 RENUKA 65 F OD IT BRVO 12 DM/HT 184 170/100 230 6/12 18 NVE Avastin/PRP 1 6/9 20
15 64151 MANNAN 40 M OS ST BRVO 24 HT/CAD/CVA 100 130/80 173 6/24 12 ME 412 AVASTIN 2 6/36 12 223 ME
16 10140 MUTHUKRISHNAN 73 M OD ST BRVO 24 Nil 180 130/90 201 1/60 20 CNP/ISCHEMIA PRP 1/60 16
17 15380 JON BEGUM 65 F OD ST BRVO 20 HT 98 170/100 221 6/24 14 NVE PRP 6/36 16
18 15405 SERMATHAYEE 58 F OD ST BRVO 24 HT/DM 230 140/100 187 6/18 18 NVD/CNP PRP 6/24 18
19 59486 GOVINDAMMAL 38 F OS CRVO 12 Nil 167 120/80 225 6/24 14 CNP Observation 6/36 16
20 479264 KUMAR 55 M OS CRVO 36 Nil 130 140/90 169 HM 14 NVE/CNP Avastin/PRP 1 HM 14 NVG
21 13706 RATHINAM 53 F OD CRVO 16 HT 152 160/100 146 3/60 18 Not done due to VH Observation 2/60 20 VH
22 20510 DANAPAL 69 M OD ST BRVO 14 DM/HT 180 170/90 247 1/60 12 ME 446 Avastin 2 1/60 14 302 ME
23 3405 PALANI 75 M OS ST BRVO 12 DM/HT 165 170/90 124 6/36 12 ME 412 Avastin 2 6/24 12 301 ME
24 472238 POONGAVANAM 60 F OS IT BRVO 36 Nil 121 140/90 157 1/60 14 ME 396 GRID 3/60 14 243 ME
25 42769 WILSENT 58 M OD ST BRVO 8 HT 160 150/100 189 6/18 12 CNP Observation 6/12 14
26 7194 PALANI 35 M OS ST BRVO 24 HT/CAD 143 140/90 165 6/24 18 NVD/CNP Avastin/PRP 1 6/18 16
27 479869 DARMAN 65 M OS CRVO 32 POAG 154 130/90 202 2/60 18 NVD PPV 1/60 20 VH
28 88563 RADHAKRISHNAN 59 M OD ST BRVO 3 DM/HT 210 150/110 162 6/24 12 NVE/NVD PRP 6/18 16
29 67262 PERIAMMAL 66 F OD CRVO 4 Nil 136 110/74 192 PL 16 CNP Observation PL 14
30 92160 ANTHONY 38 F OS SN BRVO 4 DM/HT 186 146/94 171 6/9 18 COLLATERALS Observation 6/9 16 peripheral TRD
31 53757 RANI 60 F OD CRVO 12 Nil 90 140/80 173 PL 14 CNP/ISCHEMIA PRP PL 14
32 12337 SRINIVASAN 65 M OD CRVO 20 HT 105 140/90 264 2/60 20 NVE PRP 2/60 14 NVG
33 10958 KUMAR 39 M OD ST BRVO 16 Nil 88 104/68 211 6/18 20 NVE PRP 6/18 14
34 74481 SEKAR 44 M OD ST BRVO 22 DM 156 132/88 198 4/60 12 CNP Observation 6/60 18
35 50450 MANAVALAN 72 M OS ST BRVO 18 Nil 97 114/72 231 4/60 16 ISCHEMIA Avastin 3/60 16
36 4374 SIVADAS 55 M OS Mac BRVO 26 Nil 142 132/84 165 6/18 22 COLLATERALS Observation 6/9 18
37 58383 CHANDRAN 61 M OD CRVO 14 HT 139 140/100 210 HM 18 CNP NVD PRP HM 20
38 16284 MARIMUTHU 61 M OS HCRVO 1 HT 139 140/100 210 3/60 20 COLLATERALS/ISCHEMIA Observation 2/60 20
39 4259 NAGABUSHANAM 35 M OD CRVO 8 Nil 142 140/90 163 1/60 14 CNP PRP 2/60 18
40 42405 VENU 60 M OD CRVO 12 HT 112 150/100 152 2/60 20 NVD PRP 4/60 16
41 21011 YUVARAJ 40 M OD ST BRVO 14 Nil 136 140/80 189 6/24 18 CNP Observation 6/36 20
42 8044 HARIKRISHNAN 42 M OS IT BRVO 6 Nil 110 130/80 212 6/36 14 CNP Observation 6/36 14
43 55567 MUTHUMARI 75 M OD ST BRVO 16 Nil 176 150/90 190 5/60 12 CNP/ME 235 GRID 4/60 14 243 ME
44 67973 ANJALAI 60 F OD CRVO 10 HT/DM 219 150/100 187 1/60 16 ISCHEMIA Observation HM 18
45 71201 KANNIAMMAL 64 F OD IT BRVO 20 HT 149 160/80 165 3/60 18 ME 323 GRID 2/60 18 267 ME
46 407112 ANTONY 70 M OD ST BRVO 18 POAG 98 130/80 264 4/60 16 CNP Observation/AGM 4/60 14
47 10201 DASARATHAN 62 M OD ST BRVO 30 Nil 105 140/90 183 6/60 14 NVE PRP/ Avastin 1 6/60 16
48 76411 SELVARAJ 60 M OS IT BRVO 8 HT/CAD 164 200/110 144 2/60 18 ME 356 Avastin 2 1/60 18 369 ME
49 56120 RANJITHAM 63 F OD ST BRVO 16 HT 135 130/80 190 6/60 16 CNP Observation 6/36 18
50 90555 RAMACHANDRAN 55 M OS CRVO 12 HT/DM 111 128/74 256 4/60 20 ME 642 Avastin 1 3/60 16 544 ME
51 69874 MALAR 35 F OD IT BRVO 24 Nil 105 126/76 211 6/36 12 NVE PRP 6/60 16 VH  
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ABBREVIATIONS 
1. M-male 
2. F-female 
3. OD-Right eye 
4. OS- Left eye 
5. HT-hypertension 
6. DM-diabetes mellitus 
7. CAD-coronary artery disease 
8. CVA-cerebrovascular accident 
9. ST-superotemporal 
10. SN-superonasal 
11. IT-inferotemporal 
12. IN-inferonasal 
13. VH-vitereous haemorrhage 
14. ME-macular edema 
15. CME-chronic macular edema 
16. NVD-neovascularisation disc 
17. NVE-neovascularisation elsewhere 
18. CNP-capillary non-perfusion 
19. PRP-pan retinal photocoagulation 
20. PPV-pars plana viterectomy 
21. NVG-neovascular glaucoma 
22. TRD-tractional retinal detatchment 
23. AGM-anti glaucoma medication 
24. ERM-epiretinal membrane 
25. CRVO-central  retinal vein occlusion 
26. BRVO-branch retinal vein occlusion 
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27. AV-arterio-venous 
28. VA-visual acuity 
29. RAPD-relative afferent papillary defect 
30. ERG-electroretinogram 
31. FFA-fundus fluorescein angiography 
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